Annexon Biosciences (ANNX) AI Stock Analysis

• Market Cap: $250.69M
• Dividend Yield: N/A
• Average Volume (3M): 1.40M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: N/A
• EPS Growth: 43.21%
• Country: US
• Employees: 100
• Sector: Healthcare
• Sector Strength: 66
• Industry: Biotechnology
• EPS (TTM): -1.01
• Shares Outstanding: 109,709,820
• 10 Day Avg. Volume: 2,025,725
• 30 Day Avg. Volume: 1,403,340
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 169.36
• Price to Cash Flow (P/CF): -1.80
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $14.20
• Price Target Upside: 522.81% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

Annexon Biosciences is currently in a challenging position with significant financial losses and no revenue generation. Strong financial resilience is observed through cash reserves and low debt, but bearish technical indicators suggest continued stock pressure. The negative valuation metrics reflect high future growth expectations, which remain speculative without revenue. Despite recent strategic board strengthening, the primary concern remains transitioning to revenue generation.

Positive Factors

Clinical trial success

ANX005's pivotal Phase II/III trial in GBS succeeded, showing better outcomes than the current treatments.

Market potential

ANX005's potential FDA approval in Guillain-Barré Syndrome could lead to significant market share due to its advantages over the current treatment.

Regulatory prospects

ANX005 is expected to be approved by the FDA and to become the new standard of care for GBS.

Negative Factors

Price target reduction

Revaluation of opex assumption and US and EU penetration assumptions for the GBS program reduced the price target.

Stock performance

Shares are down -55% YTD as additional regulatory clarity on ANX005 in GBS and ANX1502's POC data is awaited.

Annexon Biosciences Business Overview & Revenue Model

Company Description

Annexon Biosciences (ANNX) is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders. The company operates in the biotechnology sector and is dedicated to the development of innovative treatments that target the complement system, a part of the immune system, to address diseases across multiple therapeutic areas, including neurodegenerative and autoimmune disorders.

How the Company Makes Money

Annexon Biosciences generates revenue primarily through partnerships and collaborations with other pharmaceutical and biotechnology companies. The company's revenue model includes milestone payments, royalties, and licensing fees associated with the development and commercialization of its therapies. Annexon's potential earnings are significantly influenced by the advancement of its clinical trials, regulatory approvals, and successful commercialization of its drug candidates. As a clinical-stage company, Annexon does not yet have products on the market, thus its revenue is largely dependent on funding from strategic alliances and possibly government grants or research funding.

Annexon Biosciences Financial Statement Overview

Summary

Annexon Biosciences shows a typical pre-revenue biotechnology financial profile. Significant cash reserves support its operations, but the lack of revenue and increasing losses pose financial risks. A strong equity position and low debt levels offer some stability, yet transitioning to revenue generation remains a critical challenge.

Income Statement

Annexon Biosciences has reported zero revenue over multiple years, indicating a pre-commercial stage typical for many biotechnology firms. The company consistently records negative net income with increasing losses year-over-year, reflecting ongoing R&D and operational expenses without offsetting revenue. EBIT and EBITDA margins are negative due to lack of revenue and high expenses. Overall, the income statement highlights significant financial losses and lack of revenue generation capacity.

Balance Sheet

The balance sheet shows a strong cash position and significant stockholders' equity compared to total liabilities, indicating financial resilience. The equity ratio is healthy, suggesting the company is not overly reliant on debt financing. However, the persistent negative net income impacts the return on equity. The debt-to-equity ratio is low, reflecting minimal leverage and reduced financial risk. Despite this, the lack of revenue generation is a concern for long-term sustainability.

Cash Flow

Operating cash flow remains negative, indicating cash burn from operations without revenue support. Free cash flow is also negative, although consistent financing inflows support cash reserves. The absence of revenue means cash flow ratios, like operating cash flow to net income, remain unfavorable. Although the company maintains strong cash balances, the ongoing cash burn poses a risk if new funding is not secured.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-3.35M	0.00	-3.27M	-3.31M	-3.41M	-667.00K
	EBIT
-145.97M	-154.07M	-143.72M	-145.60M	-130.71M	-63.47M
	EBITDA
-143.85M	-154.07M	-141.57M	-143.49M	-128.57M	-62.80M
	Net Income Common Stockholders
-145.15M	-138.20M	-134.24M	-138.29M	-127.79M	-62.74M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
312.02M	312.02M	259.72M	242.66M	242.72M	351.21M
	Total Assets
350.07M	350.07M	297.67M	285.10M	287.04M	355.95M
	Total Debt
28.97M	28.97M	31.36M	32.86M	34.59M	0.00
	Net Debt
-20.53M	-20.53M	-193.75M	-107.16M	-40.25M	-268.56M
	Total Liabilities
56.97M	56.97M	47.12M	53.90M	55.13M	11.67M
	Stockholders Equity
293.11M	293.11M	250.56M	231.19M	231.91M	344.28M
Cash Flow		Free Cash Flow
-124.19M	-118.02M	-121.33M	-122.83M	-107.76M	-53.55M
	Operating Cash Flow
-116.49M	-118.01M	-121.14M	-116.31M	-106.11M	-53.09M
	Investing Cash Flow
120.38M	-218.80M	70.70M	58.44M	-88.24M	-83.16M
	Financing Cash Flow
1.01M	161.21M	135.52M	122.91M	1.79M	360.88M

Annexon Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANNX, the sentiment is Negative. The current price of 2.28 is below the 20-day moving average (MA) of 2.57, below the 50-day MA of 3.15, and below the 200-day MA of 5.23, indicating a bearish trend. The MACD of -0.20 indicates Negative momentum. The RSI at 36.77 is Neutral, neither overbought nor oversold. The STOCH value of 14.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANNX.

Annexon Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRTX	64 Neutral	$128.47B	―	-3.15%	―	11.64%	-114.72%
ALNY	59 Neutral	$36.55B	―	-414.62%	―	22.97%	38.54%
RARE	54 Neutral	$3.64B	―	-214.50%	―	29.01%	23.93%
IONS	49 Neutral	$5.32B	―	-93.03%	―	-10.48%	-18.79%
Sector *	49 Neutral	$6.88B	0.82	-52.97%	2.48%	20.92%	1.17%
CRSP	46 Neutral	$3.36B	―	-19.20%	―	-89.95%	-123.71%
ANNX	36 Underperform	$250.69M	―	-50.84%	―	―	43.21%

Annexon Biosciences Corporate Events

Annexon Biosciences Strengthens Board for Strategic Growth

Annexon Biosciences has appointed William Jones to its Board of Directors, bringing his extensive 30-year experience in the biotechnology industry to the company. This strategic move comes as Annexon prepares for the commercialization of key treatments for Guillain-Barré Syndrome and geographic atrophy, with Jones’ commercial expertise expected to enhance the company’s market positioning and execution of its commercialization strategies.